Skip to main content

Ventyx Biosciences, Inc. (VTYX)

NASDAQ: VTYX · IEX Real-Time Price · USD
18.00 -0.65 (-3.49%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap880.75M
Revenue (ttm)n/a
Net Income (ttm)-77.06M
Shares Out48.93M
EPS (ttm)-1.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,476
Open18.91
Previous Close18.65
Day's Range16.72 - 19.21
52-Week Range16.32 - 26.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VTYX

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. We believe our ability to discover and develop differentiated product candidates in an efficient manner allows us to address well-established multi-billion-dollar commercial markets and positions us to become a leader in the immunology market. Our lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor. We believe VTX9...

IndustryBiotechnology
IPO DateOct 21, 2021
CEORaju Mohan, PhD
Employees23
Stock ExchangeNASDAQ
Ticker SymbolVTYX
Full Company Profile

Financial Performance

Financial Statements

News

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies f...

2 weeks ago - GlobeNewsWire

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets

2 weeks ago - GlobeNewsWire

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to ...

ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients livin...

1 month ago - GlobeNewsWire

Ventyx Jumps Over 20% Today After NASDAQ Debut

Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket. This week Ventyx nabbed an upsized $152...

1 month ago - Benzinga

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing...

1 month ago - GlobeNewswire

Ventyx Biosciences IPO Registration Document (S-1)

Ventyx Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

Ventyx Biosciences snags $51M, hires new CMO from Horizon Therapeutics

Ventyx Biosciences is the amalgamation of three biotechs, and now it's bringing together three autoimmune experts and another $51 million to back their work. 

2 months ago - FierceBiotech

Months after a mammoth raise, Ventyx Biosciences dips back into venture well

Several months after emerging from what CEO Raju Mohan called “quiet mode” with a mammoth $114 million raise, Ventyx Biosciences is now making its plans for the clinic loud and clear.

2 months ago - EndPoints News